Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 1775 entries
Sorted by: Best Match Show Resources per page
Clinical management of nondialysis patients with chronic kidney disease: a retrospective observational study. Data from the SONDA study (Survey Of Non-Dialysis outpAtients).

International journal of nephrology and renovascular disease

Morosetti M, Gorini A, Costanzo AM, Cipriani S, Dominijanni S, Egan CG, Zappalà L, di Luzio Paparatti U.
PMID: 23550080
Int J Nephrol Renovasc Dis. 2013;6:27-37. doi: 10.2147/IJNRD.S38405. Epub 2013 Feb 18.

BACKGROUND: A lack of awareness of chronic kidney disease (CKD) often results in delayed diagnosis and inadequate treatment.PURPOSE: The objective of this study was to assess the therapeutic management and outcome of nondialysis CKD patients.METHODS: Three hundred ninety-seven patients...

Cite
Morosetti M, Gorini A, Costanzo AM, et al. Clinical management of nondialysis patients with chronic kidney disease: a retrospective observational study. Data from the SONDA study (Survey Of Non-Dialysis outpAtients). Int J Nephrol Renovasc Dis. 2013;6:27-37doi: 10.2147/IJNRD.S38405.
Morosetti, M., Gorini, A., Costanzo, A. M., Cipriani, S., Dominijanni, S., Egan, C. G., Zappalà, L., & di Luzio Paparatti, U. (2013). Clinical management of nondialysis patients with chronic kidney disease: a retrospective observational study. Data from the SONDA study (Survey Of Non-Dialysis outpAtients). International journal of nephrology and renovascular disease, 627-37. https://doi.org/10.2147/IJNRD.S38405
Morosetti, Massimo, et al. "Clinical management of nondialysis patients with chronic kidney disease: a retrospective observational study. Data from the SONDA study (Survey Of Non-Dialysis outpAtients)." International journal of nephrology and renovascular disease vol. 6 (2013): 27-37. doi: https://doi.org/10.2147/IJNRD.S38405
Morosetti M, Gorini A, Costanzo AM, Cipriani S, Dominijanni S, Egan CG, Zappalà L, di Luzio Paparatti U. Clinical management of nondialysis patients with chronic kidney disease: a retrospective observational study. Data from the SONDA study (Survey Of Non-Dialysis outpAtients). Int J Nephrol Renovasc Dis. 2013;6:27-37. doi: 10.2147/IJNRD.S38405. Epub 2013 Feb 18. PMID: 23550080; PMCID: PMC3579409.
Copy Download .nbib Format: NLM
Pre-treatment considerations in childhood hypertension due to chronic kidney disease.

World journal of nephrology

Olowu WA.
PMID: 26558187
World J Nephrol. 2015 Nov 06;4(5):500-10. doi: 10.5527/wjn.v4.i5.500.

Hypertension (HTN) develops very early in childhood chronic kidney disease (CKD). It is linked with rapid progression of kidney disease, increased morbidity and mortality hence the imperative to start anti-hypertensive medication when blood pressure (BP) is persistently > 90(th)...

Cite
Olowu WA. Pre-treatment considerations in childhood hypertension due to chronic kidney disease. World J Nephrol. 2015;4(5):500-10doi: 10.5527/wjn.v4.i5.500.
Olowu, W. A. (2015). Pre-treatment considerations in childhood hypertension due to chronic kidney disease. World journal of nephrology, 4(5), 500-10. https://doi.org/10.5527/wjn.v4.i5.500
Olowu, Wasiu Adekunle. "Pre-treatment considerations in childhood hypertension due to chronic kidney disease." World journal of nephrology vol. 4,5 (2015): 500-10. doi: https://doi.org/10.5527/wjn.v4.i5.500
Olowu WA. Pre-treatment considerations in childhood hypertension due to chronic kidney disease. World J Nephrol. 2015 Nov 06;4(5):500-10. doi: 10.5527/wjn.v4.i5.500. PMID: 26558187; PMCID: PMC4635370.
Copy Download .nbib Format: NLM
Effects of erythropoiesis-stimulating agents on heart failure patients with anemia: a meta-analysis.

Postepy w kardiologii interwencyjnej = Advances in interventional cardiology

Zhang H, Zhang P, Zhang Y, Yan J, Dong P, Wang Y, Niu X.
PMID: 27625688
Postepy Kardiol Interwencyjnej. 2016;12(3):247-53. doi: 10.5114/aic.2016.61647. Epub 2016 Aug 19.

INTRODUCTION: Heart failure (HF) is always complicated with anemia and is associated with bad prognosis in this patient population. Several studies have assessed the potential role of erythropoietin-stimulating agent (ESA) in improving cardiac function and reducing the number of...

Cite
Zhang H, Zhang P, Zhang Y, et al. Effects of erythropoiesis-stimulating agents on heart failure patients with anemia: a meta-analysis. Postepy Kardiol Interwencyjnej. 2016;12(3):247-53doi: 10.5114/aic.2016.61647.
Zhang, H., Zhang, P., Zhang, Y., Yan, J., Dong, P., Wang, Y., & Niu, X. (2016). Effects of erythropoiesis-stimulating agents on heart failure patients with anemia: a meta-analysis. Postepy w kardiologii interwencyjnej = Advances in interventional cardiology, 12(3), 247-53. https://doi.org/10.5114/aic.2016.61647
Zhang, Hengliang, et al. "Effects of erythropoiesis-stimulating agents on heart failure patients with anemia: a meta-analysis." Postepy w kardiologii interwencyjnej = Advances in interventional cardiology vol. 12,3 (2016): 247-53. doi: https://doi.org/10.5114/aic.2016.61647
Zhang H, Zhang P, Zhang Y, Yan J, Dong P, Wang Y, Niu X. Effects of erythropoiesis-stimulating agents on heart failure patients with anemia: a meta-analysis. Postepy Kardiol Interwencyjnej. 2016;12(3):247-53. doi: 10.5114/aic.2016.61647. Epub 2016 Aug 19. PMID: 27625688; PMCID: PMC5011541.
Copy Download .nbib Format: NLM
How do red blood cells know when to die?.

Royal Society open science

Arias CF, Arias CF.
PMID: 28484605
R Soc Open Sci. 2017 Apr 05;4(4):160850. doi: 10.1098/rsos.160850. eCollection 2017 Apr.

Human red blood cells (RBCs) are normally phagocytized by macrophages of splenic and hepatic sinusoids at 120 days of age. The destruction of RBCs is ultimately controlled by antagonist effects of phosphatidylserine (PS) and CD47 on the phagocytic activity...

Cite
Arias CF, Arias CF. How do red blood cells know when to die?. R Soc Open Sci. 2017;4(4):160850doi: 10.1098/rsos.160850.
Arias, C. F., & Arias, C. F. (2017). How do red blood cells know when to die?. Royal Society open science, 4(4), 160850. https://doi.org/10.1098/rsos.160850
Arias, Clemente Fernandez, and Arias, Cristina Fernandez. "How do red blood cells know when to die?." Royal Society open science vol. 4,4 (2017): 160850. doi: https://doi.org/10.1098/rsos.160850
Arias CF, Arias CF. How do red blood cells know when to die?. R Soc Open Sci. 2017 Apr 05;4(4):160850. doi: 10.1098/rsos.160850. eCollection 2017 Apr. PMID: 28484605; PMCID: PMC5414242.
Copy Download .nbib Format: NLM
Cyclic Helix B Peptide in Preservation Solution and Autologous Blood Perfusate Ameliorates Ischemia-Reperfusion Injury in Isolated Porcine Kidneys.

Transplantation direct

Yang C, Hosgood SA, Meeta P, Long Y, Zhu T, Nicholson ML, Yang B.
PMID: 27500213
Transplant Direct. 2015 Mar 10;1(2):e6. doi: 10.1097/TXD.0000000000000515. eCollection 2015 Mar.

UNLABELLED: There is a critical need to better preserve isolated organs before transplantation. We developed a novel nonerythropoiesis cyclic helix B peptide (CHBP) derived from erythropoietin, which has potent tissue protection and prolonged serum stability. The renoprotection and potential...

Cite
Yang C, Hosgood SA, Meeta P, et al. Cyclic Helix B Peptide in Preservation Solution and Autologous Blood Perfusate Ameliorates Ischemia-Reperfusion Injury in Isolated Porcine Kidneys. Transplant Direct. 2015;1(2):e6doi: 10.1097/TXD.0000000000000515.
Yang, C., Hosgood, S. A., Meeta, P., Long, Y., Zhu, T., Nicholson, M. L., & Yang, B. (2015). Cyclic Helix B Peptide in Preservation Solution and Autologous Blood Perfusate Ameliorates Ischemia-Reperfusion Injury in Isolated Porcine Kidneys. Transplantation direct, 1(2), e6. https://doi.org/10.1097/TXD.0000000000000515
Yang, Cheng, et al. "Cyclic Helix B Peptide in Preservation Solution and Autologous Blood Perfusate Ameliorates Ischemia-Reperfusion Injury in Isolated Porcine Kidneys." Transplantation direct vol. 1,2 (2015): e6. doi: https://doi.org/10.1097/TXD.0000000000000515
Yang C, Hosgood SA, Meeta P, Long Y, Zhu T, Nicholson ML, Yang B. Cyclic Helix B Peptide in Preservation Solution and Autologous Blood Perfusate Ameliorates Ischemia-Reperfusion Injury in Isolated Porcine Kidneys. Transplant Direct. 2015 Mar 10;1(2):e6. doi: 10.1097/TXD.0000000000000515. eCollection 2015 Mar. PMID: 27500213; PMCID: PMC4946457.
Copy Download .nbib Format: NLM
mTOR: Driving apoptosis and autophagy for neurocardiac complications of diabetes mellitus.

World journal of diabetes

Maiese K.
PMID: 25789103
World J Diabetes. 2015 Mar 15;6(2):217-24. doi: 10.4239/wjd.v6.i2.217.

The World Health Organization estimates that diabetes mellitus (DM) will become the seventh leading cause of death during the next two decades. DM affects approximately 350 million individuals worldwide and additional millions that remain undiagnosed are estimated to suffer...

Cite
Maiese K. mTOR: Driving apoptosis and autophagy for neurocardiac complications of diabetes mellitus. World J Diabetes. 2015;6(2):217-24doi: 10.4239/wjd.v6.i2.217.
Maiese, K. (2015). mTOR: Driving apoptosis and autophagy for neurocardiac complications of diabetes mellitus. World journal of diabetes, 6(2), 217-24. https://doi.org/10.4239/wjd.v6.i2.217
Maiese, Kenneth. "mTOR: Driving apoptosis and autophagy for neurocardiac complications of diabetes mellitus." World journal of diabetes vol. 6,2 (2015): 217-24. doi: https://doi.org/10.4239/wjd.v6.i2.217
Maiese K. mTOR: Driving apoptosis and autophagy for neurocardiac complications of diabetes mellitus. World J Diabetes. 2015 Mar 15;6(2):217-24. doi: 10.4239/wjd.v6.i2.217. PMID: 25789103; PMCID: PMC4360415.
Copy Download .nbib Format: NLM
Stability of erythropoietin repackaging in polypropylene syringes for clinical use.

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society

Marsili A, Puorro G, Pane C, de Rosa A, Defazio G, Casali C, Cittadini A, de Michele G, Florio BE, Filla A, Saccà F.
PMID: 28344481
Saudi Pharm J. 2017 Feb;25(2):290-293. doi: 10.1016/j.jsps.2016.01.003. Epub 2016 Jan 14.

No abstract available.

Cite
Marsili A, Puorro G, Pane C, et al. Stability of erythropoietin repackaging in polypropylene syringes for clinical use. Saudi Pharm J. 2016;25(2):290-293doi: 10.1016/j.jsps.2016.01.003.
Marsili, A., Puorro, G., Pane, C., de Rosa, A., Defazio, G., Casali, C., Cittadini, A., de Michele, G., Florio, B. E., Filla, A., & Saccà, F. (2017). Stability of erythropoietin repackaging in polypropylene syringes for clinical use. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 25(2), 290-293. https://doi.org/10.1016/j.jsps.2016.01.003
Marsili, Angela, et al. "Stability of erythropoietin repackaging in polypropylene syringes for clinical use." Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society vol. 25,2 (2017): 290-293. doi: https://doi.org/10.1016/j.jsps.2016.01.003
Marsili A, Puorro G, Pane C, de Rosa A, Defazio G, Casali C, Cittadini A, de Michele G, Florio BE, Filla A, Saccà F. Stability of erythropoietin repackaging in polypropylene syringes for clinical use. Saudi Pharm J. 2017 Feb;25(2):290-293. doi: 10.1016/j.jsps.2016.01.003. Epub 2016 Jan 14. PMID: 28344481; PMCID: PMC5355549.
Copy Download .nbib Format: NLM
Ferulic acid ameliorates nerve injury induced by cerebral ischemia in rats.

Experimental and therapeutic medicine

Zhang L, Wang H, Wang T, Jiang N, Yu P, Chong Y, Fu F.
PMID: 25667662
Exp Ther Med. 2015 Mar;9(3):972-976. doi: 10.3892/etm.2014.2157. Epub 2014 Dec 24.

This study was designed to investigate the protective effect of ferulic acid (FA) on nerve injury induced by cerebral ischemia. Focal cerebral ischemia was induced by occlusion of the right middle cerebral artery and reperfusion 90 min later in...

Cite
Zhang L, Wang H, Wang T, et al. Ferulic acid ameliorates nerve injury induced by cerebral ischemia in rats. Exp Ther Med. 2014;9(3):972-976doi: 10.3892/etm.2014.2157.
Zhang, L., Wang, H., Wang, T., Jiang, N., Yu, P., Chong, Y., & Fu, F. (2015). Ferulic acid ameliorates nerve injury induced by cerebral ischemia in rats. Experimental and therapeutic medicine, 9(3), 972-976. https://doi.org/10.3892/etm.2014.2157
Zhang, Leiming, et al. "Ferulic acid ameliorates nerve injury induced by cerebral ischemia in rats." Experimental and therapeutic medicine vol. 9,3 (2015): 972-976. doi: https://doi.org/10.3892/etm.2014.2157
Zhang L, Wang H, Wang T, Jiang N, Yu P, Chong Y, Fu F. Ferulic acid ameliorates nerve injury induced by cerebral ischemia in rats. Exp Ther Med. 2015 Mar;9(3):972-976. doi: 10.3892/etm.2014.2157. Epub 2014 Dec 24. PMID: 25667662; PMCID: PMC4316951.
Copy Download .nbib Format: NLM
Anti-Erythropoietin Antibody Associated Pure Red Cell Aplasia Resolved after Liver Transplantation.

Case reports in transplantation

Hung AK, Guy J, Behler CM, Lee EE.
PMID: 26240773
Case Rep Transplant. 2015;2015:286276. doi: 10.1155/2015/286276. Epub 2015 Jul 09.

Patients undergoing antiviral therapy for chronic hepatitis C often develop anemia secondary to ribavirin and interferon. Recombinant erythropoietin has been used to improve anemia associated with antiviral therapy and to minimize dose reductions, which are associated with decreased rates...

Cite
Hung AK, Guy J, Behler CM, et al. Anti-Erythropoietin Antibody Associated Pure Red Cell Aplasia Resolved after Liver Transplantation. Case Rep Transplant. 2015;2015:286276doi: 10.1155/2015/286276.
Hung, A. K., Guy, J., Behler, C. M., & Lee, E. E. (2015). Anti-Erythropoietin Antibody Associated Pure Red Cell Aplasia Resolved after Liver Transplantation. Case reports in transplantation, 2015286276. https://doi.org/10.1155/2015/286276
Hung, Annie K, et al. "Anti-Erythropoietin Antibody Associated Pure Red Cell Aplasia Resolved after Liver Transplantation." Case reports in transplantation vol. 2015 (2015): 286276. doi: https://doi.org/10.1155/2015/286276
Hung AK, Guy J, Behler CM, Lee EE. Anti-Erythropoietin Antibody Associated Pure Red Cell Aplasia Resolved after Liver Transplantation. Case Rep Transplant. 2015;2015:286276. doi: 10.1155/2015/286276. Epub 2015 Jul 09. PMID: 26240773; PMCID: PMC4512579.
Copy Download .nbib Format: NLM
Serum Levels of Growth Differentiation Factor 11 Are Independently Associated with Low Hemoglobin Values in Hemodialysis Patients.

BioResearch open access

Yamagishi S, Matsui T, Kurokawa Y, Fukami K.
PMID: 27298756
Biores Open Access. 2016 Jun 01;5(1):155-8. doi: 10.1089/biores.2016.0015. eCollection 2016.

Circulating levels of growth differentiation factor 11 (GDF11) have been shown to decrease with age in several mammalian species, and supplementation of GDF11 by heterochronic parabiosis or systemic administration reverses age-related organ damage. However, there is some controversy about...

Cite
Yamagishi S, Matsui T, Kurokawa Y, et al. Serum Levels of Growth Differentiation Factor 11 Are Independently Associated with Low Hemoglobin Values in Hemodialysis Patients. Biores Open Access. 2016;5(1):155-8doi: 10.1089/biores.2016.0015.
Yamagishi, S., Matsui, T., Kurokawa, Y., & Fukami, K. (2016). Serum Levels of Growth Differentiation Factor 11 Are Independently Associated with Low Hemoglobin Values in Hemodialysis Patients. BioResearch open access, 5(1), 155-8. https://doi.org/10.1089/biores.2016.0015
Yamagishi, Sho-Ichi, et al. "Serum Levels of Growth Differentiation Factor 11 Are Independently Associated with Low Hemoglobin Values in Hemodialysis Patients." BioResearch open access vol. 5,1 (2016): 155-8. doi: https://doi.org/10.1089/biores.2016.0015
Yamagishi S, Matsui T, Kurokawa Y, Fukami K. Serum Levels of Growth Differentiation Factor 11 Are Independently Associated with Low Hemoglobin Values in Hemodialysis Patients. Biores Open Access. 2016 Jun 01;5(1):155-8. doi: 10.1089/biores.2016.0015. eCollection 2016. PMID: 27298756; PMCID: PMC4900214.
Copy Download .nbib Format: NLM
Erythropoietin Dose and Mortality in Hemodialysis Patients: Marginal Structural Model to Examine Causality.

International journal of nephrology

Streja E, Park J, Chan TY, Lee J, Soohoo M, Rhee CM, Arah OA, Kalantar-Zadeh K.
PMID: 27298736
Int J Nephrol. 2016;2016:6087134. doi: 10.1155/2016/6087134. Epub 2016 May 19.

It has been previously reported that a higher erythropoiesis stimulating agent (ESA) dose in hemodialysis patients is associated with adverse outcomes including mortality; however the causal relationship between ESA and mortality is still hotly debated. We hypothesize ESA dose...

Cite
Streja E, Park J, Chan TY, et al. Erythropoietin Dose and Mortality in Hemodialysis Patients: Marginal Structural Model to Examine Causality. Int J Nephrol. 2016;2016:6087134doi: 10.1155/2016/6087134.
Streja, E., Park, J., Chan, T. Y., Lee, J., Soohoo, M., Rhee, C. M., Arah, O. A., & Kalantar-Zadeh, K. (2016). Erythropoietin Dose and Mortality in Hemodialysis Patients: Marginal Structural Model to Examine Causality. International journal of nephrology, 20166087134. https://doi.org/10.1155/2016/6087134
Streja, Elani, et al. "Erythropoietin Dose and Mortality in Hemodialysis Patients: Marginal Structural Model to Examine Causality." International journal of nephrology vol. 2016 (2016): 6087134. doi: https://doi.org/10.1155/2016/6087134
Streja E, Park J, Chan TY, Lee J, Soohoo M, Rhee CM, Arah OA, Kalantar-Zadeh K. Erythropoietin Dose and Mortality in Hemodialysis Patients: Marginal Structural Model to Examine Causality. Int J Nephrol. 2016;2016:6087134. doi: 10.1155/2016/6087134. Epub 2016 May 19. PMID: 27298736; PMCID: PMC4889858.
Copy Download .nbib Format: NLM
Serum Erythropoietin Levels in Pediatric Hematologic Disorders and Impact of Recombinant Human Erythropoietin Use.

Turkish journal of haematology : official journal of Turkish Society of Haematology

Çetin M, Ünal Ş, Gümrük F, Gürgey A, Altay Ç.
PMID: 27265276
Turk J Haematol. 2009 Jun 05;26(2):72-6.

OBJECTIVE: In anemic patients, the correlation between serum erythropoietin (sEpo) level and the severity of anemia has been reported previously. However, in different anemia groups, different sEpo levels are measured in patients with similar hemoglobin levels and the etiology...

Cite
Çetin M, Ünal Ş, Gümrük F, et al. Pediatrik hematolojik hastalıklarda serum eritropoetin düzeyleri ve rekombinan insan kaynaklı eritropoetin kullanımının olası etkileri. Serum Erythropoietin Levels in Pediatric Hematologic Disorders and Impact of Recombinant Human Erythropoietin Use. Turk J Haematol. 2009;26(2):72-6
Çetin, M., Ünal, �. �., Gümrük, F., Gürgey, A., & Altay, �. �. (2009). Pediatrik hematolojik hastalıklarda serum eritropoetin düzeyleri ve rekombinan insan kaynaklı eritropoetin kullanımının olası etkileri. Serum Erythropoietin Levels in Pediatric Hematologic Disorders and Impact of Recombinant Human Erythropoietin Use. Turkish journal of haematology : official journal of Turkish Society of Haematology, 26(2), 72-6.
Çetin, Mualla, et al. "Pediatrik hematolojik hastalıklarda serum eritropoetin düzeyleri ve rekombinan insan kaynaklı eritropoetin kullanımının olası etkileri." Serum Erythropoietin Levels in Pediatric Hematologic Disorders and Impact of Recombinant Human Erythropoietin Use. Turkish journal of haematology : official journal of Turkish Society of Haematology vol. 26,2 (2009): 72-6.
Çetin M, Ünal Ş, Gümrük F, Gürgey A, Altay Ç. Pediatrik hematolojik hastalıklarda serum eritropoetin düzeyleri ve rekombinan insan kaynaklı eritropoetin kullanımının olası etkileri. Serum Erythropoietin Levels in Pediatric Hematologic Disorders and Impact of Recombinant Human Erythropoietin Use. Turk J Haematol. 2009 Jun 05;26(2):72-6. PMID: 27265276.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 1775 entries